ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,127.79
1.26%
Dow Jones
38,675.68
1.18%
US Dollar vs MXN
16.9724
0.00%
Brent Oil
82.765
0.00%
Bitcoin
64,065.11
0.27%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Annexon Inc (ANNX)

  7. Annexon Inc (ANNX) Noticias

ANNX Annexon Inc

5.10
0.44 (9.44%)
03 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Annexon Inc ANNX NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.44 9.44% 5.10 23:00:04
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
4.75 4.69 5.06 4.88 4.66
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
16/4/202408:00GLOBETurnstone Biologics Appoints William Waddill to its Board of..
21/2/202415:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/2/202415:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/2/202415:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/2/202414:15EDGAR2Form 144 - Report of proposed sale of securities
20/2/202414:12EDGAR2Form 144 - Report of proposed sale of securities
14/2/202419:46EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202418:59EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/2/202418:56EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/2/202418:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/2/202414:45EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
13/2/202418:23EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
13/2/202417:57EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
12/2/202415:24EDGAR2Form SC 13G - Statement of acquisition of beneficial..
12/2/202414:45EDGAR2Form 144 - Report of proposed sale of securities
12/2/202414:41EDGAR2Form 144 - Report of proposed sale of securities
12/2/202414:39EDGAR2Form 144 - Report of proposed sale of securities
23/1/202416:00EDGAR2Form 4/A - Statement of changes in beneficial ownership of..
23/1/202415:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202415:09EDGAR2Form 8-K - Current report
07/1/202419:00GLOBEAnnexon Outlines 2024 Priorities with Late-Stage Clinical..
29/12/202315:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/12/202315:50EDGAR2Form 144 - Report of proposed sale of securities
27/12/202305:30GLOBEAnnexon Biosciences to Present at the 42nd Annual J.P...
22/12/202316:28EDGAR2Form 8-K/A - Current report: [Amend]
21/12/202315:09EDGAR2Form 8-K - Current report
21/12/202315:05EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
20/12/202316:27GLOBEAnnexon Announces Pricing of $125.0 Million Underwritten..
20/12/202316:24EDGAR2Form FWP - Filing under Securities Act Rules 163/433 of free..
20/12/202316:17EDGAR2Form 8-K - Current report
20/12/202316:10GLOBEAnnexon Outlines Global Registrational Program for ANX007 in..
20/12/202316:08GLOBEAnnexon Reports Phase 1 Results for ANX1502, its Oral Small..
18/12/202315:01GLOBEAnnexon Reports Inducement Grants to New Employees Under..
22/11/202315:01GLOBEAnnexon Biosciences to Participate in the 6th Annual..
13/11/202315:10EDGAR2Form 8-K - Current report
13/11/202305:30GLOBEAnnexon Reports Significant Progress with its Priority..
09/11/202305:30GLOBEAnnexon Biosciences to Participate in 2023 Jefferies London..
24/10/202315:30EDGAR2Form 8-K - Current report
24/10/202305:30GLOBEAnnexon Receives PRIME Designation from the EMA for ANX007..
18/10/202315:01GLOBEAnnexon Reports Inducement Grants to New Employees Under..
11/10/202315:44EDGAR2Form 8-K - Current report
10/10/202305:30GLOBEAnnexon Announces Clinical and Regulatory Progress for..
19/9/202305:30GLOBEAnnexon Biosciences to Participate in the 2023 Cantor Global..
18/9/202315:01GLOBEAnnexon Reports Inducement Grant to New Employee Under..
07/8/202315:12EDGAR2Form 8-K - Current report
07/8/202315:06EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/8/202305:30GLOBEAnnexon Highlights Recent Pipeline and Business Progress and..
02/8/202316:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/8/202316:06EDGAR2Form 3 - Initial statement of beneficial ownership of..
02/8/202315:01GLOBEAnnexon Reports Inducement Grant to New Employee Under..

Su Consulta Reciente

NASDAQ
ANNX
Annexon
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados